This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Alcoholic liver disease (ALD) is a medical condition caused by excessive and prolonged consumption of alcohol. The primary symptom of ALD is liver inflammation and damage, which can lead to cirrhosis, liver cancer, and ultimately, liver failure. ALD is the most common form of chronic liver disease in the United States, and it is estimated that one in four people who consume alcohol are at risk for developing the condition. The liver is responsible for metabolizing alcohol, but when excessive amounts of alcohol are consumed, the liver is unable to break down the alcohol properly, leading to the buildup of toxic waste products in the liver. This causes inflammation and damage to the liver cells, leading to scarring, or cirrhosis. Cirrhosis is the most severe form of ALD and can lead to liver failure. Other symptoms of ALD may include jaundice (yellowing of the skin and whites of the eyes), fatigue, abdominal pain, nausea, and weight loss. ALD is usually diagnosed after a physical exam, blood tests, and imaging tests. Treatment for ALD typically involves reducing alcohol intake and abstaining from alcohol entirely. Medication may also be prescribed to reduce inflammation and scarring in the liver, and lifestyle changes such as a healthy diet and regular exercise are also recommended. If untreated, ALD can be fatal. It is important to reduce alcohol intake or abstain from it completely in order to prevent the progression of ALD and its complications.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States